NCT00583713CompletedPhase 1
An Open Label Study to Assess the Effect of BLI800 on Safety and Clinical Chemistry Parameters
Braintree Laboratories0 sites18 target enrollmentStarted: August 2007Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Enrollment
- 18
- Primary Endpoint
- Maximum Observed Concentration (Cmax)
Study Overview
Brief Summary
To evaluate and compare the effects on safety measures and clinical chemistry after BLI800 in two groups of patients and one group of healthy controls. The patient groups will be those with mild or moderate hepatic impairment or moderate renal disease.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Are male or female adults who are:
- •With Child-Pugh Hepatic Dysfunction Stage A or B, or
- •With Moderate Renal Disease or
- •Healthy subjects matched to those who are enrolled in this study
- •Subjects who are considered to have only clinically non-significant conditions, as judged by the Principal Investigator and based on physical examination, laboratory profiles, medical history and ECG.
- •Female subjects who are not surgically sterile (i.e., having had a hysterectomy, bilateral oophorectomy or tubal ligation) or who are not at least 2 years naturally postmenopausal must agree to use an acceptable form of contraception.
- •Provide voluntary consent in writing to participate in this study.
Exclusion Criteria
- •Subjects with known or suspected ileus, severe ulcerative colitis, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, or megacolon.
- •Subjects with impaired consciousness that predisposes them to pulmonary aspiration.
- •Subjects who, in the opinion of the Principal Investigator, have uncontrolled clinically significant pre-existing electrolyte disturbances, based on the Screening visit laboratory results.
- •Subjects with present or prior NYHA Functional Classification grade III or IV congestive heart failure.
- •Subjects who are pregnant or lactating, or intending to become pregnant during the study.
- •Subjects of childbearing potential who refuse a pregnancy test.
- •Subjects who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days.
- •Subjects with a history of allergic or adverse response to any BLI-800 component.
- •Subjects who donated more than one pint of blood within 30 days prior to the study.
- •Subjects who donated plasma within 7 days prior to the study.
- •Subjects who had an abnormal diet or substantial changes in eating habits within 30 days prior to the start of the study.
- •Subjects who have had a bowel cleansing procedure within the past month or who have taken a laxative within the 5 days (120 hours) prior to dosing or who require a laxative every day.
- •Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures.
Arms & Interventions
Renal Group
Experimental
Patients with moderate renal impairment
Intervention: BLI-800 (Drug)
Healthy volunteers
Active Comparator
Healthy volunteers
Intervention: BLI-800 (Drug)
Hepatic Group
Experimental
Patients with mild/moderate hepatic impairment.
Intervention: BLI-800 (Drug)
Outcomes
Primary Outcomes
Maximum Observed Concentration (Cmax)
Time Frame: 1 day
Time to Maximum Concentration
Time Frame: 1 day
Terminal Half-life
Time Frame: 1 day
Area Under the Curve for the 24-hour Dosing Interval
Time Frame: 1 day
Elimination Rate Constant
Time Frame: 1 day
Secondary Outcomes
- Urinary Sulfate Concentration(pre-dose to 6 days post-dose)
Investigators
Similar Trials
Completed
Phase 3
BLI-800-301: BLI-800 vs an Active Control Bowel Preparation in Adult Subjects Undergoing ColonoscopyColonoscopyNCT00503607Braintree Laboratories400
Completed
Phase 3
BLI-800-302: BLI-800 vs an Active Control Bowel Preparation in Adult Subjects Undergoing ColonoscopyColonoscopyNCT00503815Braintree Laboratories360
Completed
Phase 3
A Safety Study of 3 Different Bowel Cleansing PreparationsColonoscopyBowel PreparationEndoscopyNCT01501513Braintree Laboratories541
Completed
Phase 4
An Open-Label Preference Evaluation of BLI800ColonoscopyNCT04214301Braintree Laboratories40
Completed
Phase 2
A Safety and Efficacy Evaluation of Topical Treatments for Moderate-Severe Facial Acne VulgarisAcne VulgarisNCT02604680Braintree Laboratories509